Clinical Trial Update: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and axatilimab in relapsed or refractory classical Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Axatilimab (axatilimab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Utah | Conditions: Hodgkin Lymphoma | Phase 2 | Status: RECRUITING